Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Other Non-Current Assets (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Other Non-Current Assets over the past 15 years, most recently at $6.6 million for Q2 2025.

  • For Q2 2025, Other Non-Current Assets rose 15.79% year-over-year to $6.6 million; the TTM value through May 2025 reached $6.6 million, up 15.79%, while the annual FY2025 figure was $6.6 million, 15.79% up from the prior year.
  • Other Non-Current Assets for Q2 2025 was $6.6 million at Lifecore Biomedical, Inc. \De\, up from $4.9 million in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $90.2 million in Q1 2021 and troughed at $2.6 million in Q4 2024.
  • A 5-year average of $22.6 million and a median of $5.3 million in 2024 define the central range for Other Non-Current Assets.
  • On a YoY basis, Other Non-Current Assets climbed as much as 6045.68% in 2021 and fell as far as 98.23% in 2021.
  • Year by year, Other Non-Current Assets stood at $3.1 million in 2021, then soared by 252.94% to $10.9 million in 2022, then plummeted by 62.58% to $4.1 million in 2023, then plummeted by 36.96% to $2.6 million in 2024, then soared by 156.25% to $6.6 million in 2025.
  • Business Quant data shows Other Non-Current Assets for LFCR at $6.6 million in Q2 2025, $4.9 million in Q1 2025, and $2.6 million in Q4 2024.